Latest News and Press Releases

FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic...

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through...

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through...

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive...

BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric...

BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...

Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies ...

Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank ...

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission  Company successfully completed the first...